BioPorto (Investment Case): Q1 2026, advancement on the three pillars central to the long-term potential

In connection with the publication of BioPorto's Q1 2026 interim results, we have updated our investment case.Our investment case covers the key investment reasons, risks, and valuation perspectives.

Q1 2026 marked a quarter of execution on the Forward Strategy presented in November 2025. Revenue grew 23% to DKK 9.4m (32% at constant exchange rates), driven by 33% growth in NGAL revenue to DKK 6.0m, primarily from US NGAL RUO sales, where the 12-month rolling figure reached DKK 19.3m, up 36% year-over-year at constant exchange rates. The adjusted EBITDA loss narrowed by 36% to DKK 17.9m, compared to DKK 28.1m in Q1 2025, and was in line with expectations despite continued elevated R&D costs from the adult clinical study. The cash position was DKK 39.6m at end-Q1 2026, before rising to DKK 98m on 8 April following the initial USD 9m payment from the antibody divestment.

The full-year 2026 guidance is maintained at DKK 38-48m in total revenue (-6% to +19% growth), DKK 33-42m in NGAL revenue, and an adj. EBITDA loss of DKK 58-68m. Growth is expected to be back-end loaded as hospital adoption scales.

Q1 2026 delivered advancement on the three pillars central to the long-term investment case.

First, on the regulatory front, the FDA pre-submission package for the adult urine NGAL test was filed end of March 2026, with FDA feedback expected in mid-June 2026 - a near-term catalyst that will set the path toward the targeted U.S. 510(k) clearance for adults at end-2027.

Second, KDIGO published its draft 2026 AKI guideline at the end of March, recognising AKI and AKD as a continuum and supporting the use of structural biomarkers like NGAL for earlier diagnosis. BioPorto submitted its input to KDIGO in early May, and the final updated guidelines are expected late 2026. KDIGO inclusion is a direct prerequisite for the 2028 ambitions, shifting NGAL from a discretionary add-on to a compliance tool and driving pull-through demand and reimbursement eligibility.

Third, on the access and health economics pillar, four new US hospitals were on-boarded in Q1 2026, bringing the total to 48 active US sites and supporting the full-year target of 60+ by year-end. In parallel, BioPorto continues to build the health economics case for NGAL, addressing AKI as a USD 6bn annual cost burden in the US (GBP 1bn in the UK), where costs escalate non-linearly through ICU admission, dialysis and CKD, and where early NGAL-guided intervention can interrupt the cost curve.

In addition to executing on the three pillars, the divestment of the Antibody Business to Janel Life Sciences, completed on 8 April 2026 for up to USD 10.5m, materially de-risked the investment case. The transaction secured the capital needed to bridge to cash flow positive in H1 2028, removing the funding gap previously expected and reducing dilution risk.

Our investment case covers the key investment reasons, risks, and valuation perspectives.

The key investment reasons centre on continued commercialisation of BioPorto's NGAL test through partnerships with Roche and Beckman Coulter, supported by an FDA-cleared pediatric product and strong health economics in a market with high unmet need. The directly addressable ICU market is around USD 700m annually, growing ~5%, with adult FDA approval targeted for end-2027 potentially expanding the addressable market by roughly 20x relative to the current approved pediatric segment.

The key risks include the inherent uncertainty of FDA adult clearance, third-party risk from partner-dependent growth (which has been slower than expected), residual execution risk on hospital adoption and reimbursement traction, and the potential for generic competition after patent expiry in late 2028, although the lengthy IVD validation process on each instrument platform acts as a de facto barrier.

From a valuation perspective, only minor updates to our model-implied PoS have been made following Q1 2026 results. Across our three scenarios, the market currently implies a base-case probability of success of ~58%, with the bear case at 77% and the bull case at 43%. The base case PoS remains low for a diagnostics company with a product already on the market and key catalysts now delivered, suggesting upside if BioPorto continues to execute against its strategic and regulatory milestones.

A re-rating of the PoS hinges on delivering on the three pillars: i) FDA clearance and US market entry for adults, ii) strong inclusion in the KDIGO guidelines, and iii) establishing access through expanded hospital adoption and strong health economics for early AKI detection using NGAL.

For more insights into the results and the outlook, you can watch the management presentation of the Q1 2026 results here: 

BioPorto - Q1 2026 Event

Disclaimer: HC Andersen Capital receives payment from BioPorto for a Digital IR/Corporate Visibility subscription agreement /Michael Friis 14:30 22/05/2026